- Home
- TGB vs KROS Comparison
TGB vs KROS Comparison
Compare TGB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- KROS
- Stock Information
- Founded
- TGB 1966
- KROS 2015
- Country
- TGB Canada
- KROS United States
- Employees
- TGB N/A
- KROS N/A
- Industry
- TGB Precious Metals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- KROS Health Care
- Exchange
- TGB Nasdaq
- KROS Nasdaq
- Market Cap
- TGB 698.1M
- KROS 565.0M
- IPO Year
- TGB N/A
- KROS 2020
- Fundamental
- Price
- TGB $3.08
- KROS $14.32
- Analyst Decision
- TGB Hold
- KROS Buy
- Analyst Count
- TGB 1
- KROS 13
- Target Price
- TGB $5.00
- KROS $20.63
- AVG Volume (30 Days)
- TGB 7.3M
- KROS 461.3K
- Earning Date
- TGB 08-06-2025
- KROS 08-11-2025
- Dividend Yield
- TGB N/A
- KROS N/A
- EPS Growth
- TGB N/A
- KROS N/A
- EPS
- TGB N/A
- KROS 0.11
- Revenue
- TGB $417,640,101.00
- KROS $214,713,000.00
- Revenue This Year
- TGB $18.29
- KROS $5,390.70
- Revenue Next Year
- TGB $38.25
- KROS N/A
- P/E Ratio
- TGB N/A
- KROS $131.42
- Revenue Growth
- TGB 7.89
- KROS 91657.70
- 52 Week Low
- TGB $1.67
- KROS $9.12
- 52 Week High
- TGB $3.68
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- TGB 43.15
- KROS 54.05
- Support Level
- TGB $2.96
- KROS $14.25
- Resistance Level
- TGB $3.45
- KROS $14.81
- Average True Range (ATR)
- TGB 0.16
- KROS 0.49
- MACD
- TGB -0.07
- KROS 0.01
- Stochastic Oscillator
- TGB 18.12
- KROS 56.02
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.